### DRUG:
**OCTREOTIDE**

### PRESENTATION:
- Ampoule: 100 microgram/mL
- Unit dose syringes: Supplied by Pharmacy.

### ACTION & INDICATION:
Synthetic analogue of Somatostatin (a growth hormone inhibitor) which inhibits insulin release.

- Used to treat:
  1. hypoglycaemia due to hyperinsulinism unresponsive to diazoxide and glucose
  2. "short bowel syndrome"
  3. chylothorax

### DOSE:
- **Subcutaneous/intravenous:**
  1 - 5 microgram/kg/dose 6 - 8 hourly
  Titrate dose to patients requirements to a maximum dose of 10 microgram/kg/dose
- **Intravenous infusion:** For treatment of chylothorax
  1 microgram/kg/hour .Titrate dose upwards as required.
  Maximum dose: 7 microgram/kg/hour

### PREPARATION:
- **IV:** Use undiluted solution or dilute to a strength of from 5 to 250 microgram per mL
  - ie 100 microgram diluted to 20mL = 5 microgram per mL

### ADMINISTRATION:
- Subcutaneous injection.
- Intravenous infusion.

### ADVERSE EFFECTS:
- Local reaction at injection site.
- GI side effects – vomiting, diarrhoea, abdominal discomfort.

### COMMENTS:
Chyle production should decrease significantly within 24 hours
Check PGL pre-dose and as requested.
Refrigereate and protect from light.
Diluted solution is stable for eight hours only.

### REFERENCES:
- Neofax 2013
- BNF for Children 2013
- Australian Injectable DRUGS Handbook 5th Ed SHPA

### DATE:
October 2013